Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at Cowen Inc.
Aura Biosciences, Inc. (AURA)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
AURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AURA alerts
High impacting Aura Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
AURA
News
- Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value [Seeking Alpha]Seeking Alpha
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at BTIG Research from $21.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 TrialGlobeNewswire
AURA
Earnings
- 5/9/24 - Beat
AURA
Sec Filings
- 10/29/24 - Form 144
- 10/29/24 - Form 144
- 10/29/24 - Form 144
- AURA's page on the SEC website